TR201907241T4 - IL-17 inhibitörü terapisi etkinliği için bir biyo-işaret olarak lipokalin 2. - Google Patents

IL-17 inhibitörü terapisi etkinliği için bir biyo-işaret olarak lipokalin 2. Download PDF

Info

Publication number
TR201907241T4
TR201907241T4 TR2019/07241T TR201907241T TR201907241T4 TR 201907241 T4 TR201907241 T4 TR 201907241T4 TR 2019/07241 T TR2019/07241 T TR 2019/07241T TR 201907241 T TR201907241 T TR 201907241T TR 201907241 T4 TR201907241 T4 TR 201907241T4
Authority
TR
Turkey
Prior art keywords
lipocalin
biomarker
inhibitor therapy
therapy efficacy
efficacy
Prior art date
Application number
TR2019/07241T
Other languages
English (en)
Inventor
Samuel Platt Adam
Edward Rapecki Stephen
Fortunato Mara
Leigh Rundle Jon
Alfred Smith Paul
Sairfull Watt Gillian
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of TR201907241T4 publication Critical patent/TR201907241T4/tr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mevcut buluş IL-17'nin aracılık ettiği hastalıklar için ve bir hastanın anti-IL-17 terapisi cevabını izlemek için bir biyo-işaret olarak lipokalin 2'nin (LCN2) kullanımını sağlamaktadır.
TR2019/07241T 2011-01-07 2012-01-09 IL-17 inhibitörü terapisi etkinliği için bir biyo-işaret olarak lipokalin 2. TR201907241T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1100282.1A GB201100282D0 (en) 2011-01-07 2011-01-07 Biological methods

Publications (1)

Publication Number Publication Date
TR201907241T4 true TR201907241T4 (tr) 2019-06-21

Family

ID=43663952

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/07241T TR201907241T4 (tr) 2011-01-07 2012-01-09 IL-17 inhibitörü terapisi etkinliği için bir biyo-işaret olarak lipokalin 2.

Country Status (5)

Country Link
EP (2) EP3534159A1 (tr)
ES (1) ES2728253T3 (tr)
GB (1) GB201100282D0 (tr)
TR (1) TR201907241T4 (tr)
WO (1) WO2012093254A1 (tr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ610592A (en) 2010-11-04 2015-03-27 Boehringer Ingelheim Int Anti-il-23 antibodies
GB2495719A (en) 2011-10-18 2013-04-24 Epiontis Gmbh Epigenetic markers of IL-17 positive T cells
KR102124758B1 (ko) 2012-05-03 2020-06-19 베링거 인겔하임 인터내셔날 게엠베하 항-ｉｌ-23ｐ19 항체
CU24300B1 (es) * 2013-02-08 2017-12-08 Novartis Ag Anticuerpos anti-il-17a útiles en el tratamiento de trastornos autoinmunes e inflamatorios
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
TWI711629B (zh) 2014-09-03 2020-12-01 德商包林格因蓋爾漢國際股份有限公司 靶向IL-23A與TNF-α之化合物及其用途
CA2998349A1 (en) 2015-09-17 2017-03-23 Amgen Inc. Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
WO2017136497A1 (en) * 2016-02-03 2017-08-10 The Cleveland Clinic Foundation Detection and treatment of il-17 and il-13 related conditions
CN111187846A (zh) * 2020-03-10 2020-05-22 中国医学科学院医学生物学研究所 检测树鼩lcn2基因转录水平的引物、试剂盒及方法
CN114518416B (zh) * 2020-11-20 2024-05-24 上海交通大学医学院附属瑞金医院 一种判断银屑病对il-17a抗体应答反应及其复发的标志物

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
IL91501A (en) 1988-09-02 1998-03-10 Dyax Corp Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5807683A (en) 1992-11-19 1998-09-15 Combichem, Inc. Combinatorial libraries and methods for their use
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
US5738996A (en) 1994-06-15 1998-04-14 Pence, Inc. Combinational library composition and method
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
US6793919B2 (en) 2000-10-18 2004-09-21 Immunex Corporation Methods for treating rheumatoid arthritis using IL-17 antagonists
WO2005051422A1 (en) 2003-11-21 2005-06-09 Celltech R & D Limited Method for the treatment of multiple sclerosis by inhibiting il-17 activity
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
WO2006125105A2 (en) 2005-05-19 2006-11-23 Wyeth Methods and compositions for treating and diagnosing multiple sclerosis
DK1963368T6 (da) 2005-12-13 2020-06-29 Lilly Co Eli Anti-il-17-antistoffer
BRPI0620914A2 (pt) * 2005-12-28 2011-11-29 Centocor Inc marcadores e métodos para avaliar e tratar psorìase e distúrbios relacionados
AU2007226627B2 (en) 2006-03-10 2012-09-20 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
CN104004088B (zh) 2007-09-26 2017-11-07 Ucb医药有限公司 双特异性抗体融合物
JP2011519911A (ja) 2008-05-05 2011-07-14 ノヴィミュンヌ エスア 抗ｉｌ１７ａ／ｉｌ−１７ｆ交差反応抗体及びその使用方法
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
CN102164965B (zh) 2008-09-26 2016-03-30 Ucb医药有限公司 生物产品
WO2010062663A1 (en) * 2008-11-03 2010-06-03 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
CN102497833B (zh) 2009-07-14 2014-12-03 波技术视觉系统公司 眼科手术测量系统
EP2475682B1 (en) 2009-09-10 2018-01-31 UCB Biopharma SPRL Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies

Also Published As

Publication number Publication date
WO2012093254A1 (en) 2012-07-12
ES2728253T3 (es) 2019-10-23
GB201100282D0 (en) 2011-02-23
EP2661627B1 (en) 2019-03-13
EP3534159A1 (en) 2019-09-04
EP2661627A1 (en) 2013-11-13

Similar Documents

Publication Publication Date Title
TR201907241T4 (tr) IL-17 inhibitörü terapisi etkinliği için bir biyo-işaret olarak lipokalin 2.
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1119533T1 (el) Νεοι θεραπευτικοι παραγοντες
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1120246T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
EA201500362A1 (ru) Ингибиторы rho-киназы
CR20110560A (es) Métodos de tratamiento para tumores sólidos
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
EA201170521A1 (ru) Новые соединения
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA201390711A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
CR20130045A (es) Compuestos terapéuticos
CR20130517A (es) Tratamientos combinados para neoplasias hematológicas malignas
EP3447491A3 (en) Diagnosis and treatments relating to th2 inhibition
TR201904638T4 (tr) pKal aracılı rahatsızlıkların değerlendirilmesi, analizi ve tedavisi.
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
MX351943B (es) Compuestos inhibidores de metaloenzima.
BR112015029970A2 (pt) inibidores de cinase
EA201290677A1 (ru) Соединения обратного амида в качестве ингибиторов протеиндеацетилазы и способы их применения
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
TR201904980T4 (tr) Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты